Tan Jack Wei Chieh, Yeo Khung Keong, Laird John R
Division of Cardiovascular Medicine, University of California Davis Medical Center, 4860 Y Street, Sacramento, CA 95817, USA.
J Vasc Interv Radiol. 2008 Jun;19(6 Suppl):S9-S17. doi: 10.1016/j.jvir.2007.12.452.
Endovascular treatment of infrarenal abdominal aortic aneurysm (AAA) offers a less invasive alternative to conventional open repair. Currently, only four devices are Food and Drug Administration (FDA)-approved for use in endovascular aneurysm repair (EVAR) of AAA in the United States. All four devices are associated with a high technical success rate and less morbidity than open surgical repair. Each device has its inherent design advantages and disadvantages that must be matched with patient and AAA characteristics. This review will discuss and compare the technology and procedural outcomes data of the current FDA-approved EVAR devices.
肾下腹主动脉瘤（AAA）的血管内治疗为传统开放修复提供了一种侵入性较小的替代方法。目前，在美国仅有四种器械获得食品药品监督管理局（FDA）批准用于AAA的血管内动脉瘤修复（EVAR）。与开放手术修复相比，所有这四种器械均具有较高的技术成功率和较低的发病率。每种器械都有其固有的设计优缺点，必须与患者和AAA的特征相匹配。本综述将讨论并比较当前FDA批准的EVAR器械的技术和手术结果数据。
